RxDoctor Payments Data

Lori Robbins, MD

Gastroenterology · Charleston, SCNPI 1629417761

Payments from drug & device makers

$8,934in general payments, 2019–2025

Across 532 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$881
  • Johnson & Johnson$621
  • QOL Medical, LLC$534
  • Bristol Myers Squibb$523
  • Ardelyx, Inc.$398
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$8,88999%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,934 in reported general payments places this provider in the 70th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$152,573
Medicare patients
434
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$579,799
Humira(Cf) PenAdalimumab11$74,866
LinzessLinaclotide88$65,531
MotegrityPrucalopride Succinate69$57,185
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates159$10,804
Mesalamine20$8,105
Budesonide DrBudesonide12$6,086
SutabSod Sulf/Pot Chloride/Mag Sulf37$5,924
Omeprazole299$4,293
Mesalamine ErMesalamine16$2,221
Famotidine131$1,708
Colestipol Hcl25$1,374
Rabeprazole Sodium39$962
Esomeprazole Magnesium34$861
Pantoprazole Sodium76$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$621$579,79917 claims
AbbVieLinzess$2,450$65,53188 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$214$57,18569 claims
Braintree Laboratories, Inc.Sutab$216$5,92437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →